Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Ophthalmologe ; 103(9): 777-82, 2006 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-16819661

RESUMO

AIM: This retrospective study should examine and judge the surgical indications and the therapeutic possibilities as well as their complications in patients with ocular manifestations of Marfan syndrome (MFS) diagnosed according to the criteria of the Ghent nosology. PATIENTS AND METHODS: The study included 17 patients. Operative indications were increasing subluxation of the lens, retinal detachments and secondary glaucoma. The operative procedure depended on patient age and findings. Eleven MFS patients were operated in both eyes and six MFS patients in one eye. RESULTS: Stabilization or functional improvement of visual acuity could be achieved in all patients in whom no disorders limiting visual acuity or amblyopia were present preoperatively. In six eyes of five patients, lens insertion was accomplished via a pars plana approach. Lens removal without implantation of an intraocular lens was performed in 16 eyes of 10 patients. Pars plana vitrectomy was accomplished in 12 eyes. Complications were well controlled by pars plana vitrectomy. CONCLUSIONS: Difficult preoperative situations and postoperative complications are not rare in MFS patients. However, they can be controlled well by means of modern vitreous surgery.


Assuntos
Oftalmopatias/cirurgia , Síndrome de Marfan/cirurgia , Procedimentos Cirúrgicos Oftalmológicos/métodos , Transtornos da Visão/prevenção & controle , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Oftalmopatias/diagnóstico , Feminino , Humanos , Masculino , Síndrome de Marfan/diagnóstico , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Transtornos da Visão/diagnóstico , Acuidade Visual
2.
Ophthalmologe ; 103(6): 463-70, 2006 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-16763862

RESUMO

The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.


Assuntos
Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/efeitos adversos , Neovascularização de Coroide/tratamento farmacológico , Degeneração Macular/tratamento farmacológico , Inibidores da Angiogênese/administração & dosagem , Inibidores da Angiogênese/efeitos adversos , Anticorpos Monoclonais Humanizados , Bevacizumab , Neovascularização de Coroide/etiologia , Ensaios Clínicos como Assunto , Aprovação de Drogas , Rotulagem de Medicamentos , Medicina Baseada em Evidências , Humanos , Injeções Intralesionais , Degeneração Macular/complicações , Padrões de Prática Médica , Resultado do Tratamento , Corpo Vítreo
3.
Ophthalmologe ; 103(6): 537-51; quiz 552-3, 2006 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-16763870

RESUMO

Pseudoxanthoma elasticum (PXE) is an inherited disorder that is associated with accumulation of mineralized and fragmented elastic fibers in the skin, vessel walls, and Bruch's membrane. Clinically, patients exhibit characteristic lesions of the skin (soft, ivory-colored papules in a reticular pattern that predominantly affect the neck), the posterior segment of the eye (peau d'orange, angioid streaks, choroidal neovascularizations), and the cardiovascular system (peripheral arterial occlusive disease, coronary occlusion, gastrointestinal bleeding). There is no causal therapy. Recent studies suggest that PXE is inherited almost exclusively as an autosomal recessive trait. Its prevalence has been estimated to be 1:25,000-100,000. The ABCC6 gene on chromosome 16p13.1 is associated with the disease. Mutations within the ABCC6 gene cause reduced or absent transmembraneous transport that leads to accumulation of substrate and calcification of elastic fibers. Although based on clinical features the diagnosis appears readily possible, variability in phenotypic expressions and the low prevalence may be responsible that the disease is underdiagnosed. This review covers current knowledge of PXE and presents therapeutic approaches.


Assuntos
Neovascularização de Coroide/diagnóstico , Neovascularização de Coroide/terapia , Pseudoxantoma Elástico/diagnóstico , Pseudoxantoma Elástico/terapia , Neovascularização de Coroide/epidemiologia , Neovascularização de Coroide/etiologia , Humanos , Guias de Prática Clínica como Assunto , Padrões de Prática Médica , Pseudoxantoma Elástico/complicações , Pseudoxantoma Elástico/epidemiologia
4.
Artigo em Inglês | MEDLINE | ID: mdl-15763436

RESUMO

OBJECTIVE: The pilot study is intended to show whether prostaglandin E1 (PGE1) infusions are able to stop the gradual vision loss in dry age-related macular degeneration (AMD) and, further, to stabilize or improve visual acuity. METHODS: With PGE1 infusions 11 patients with different forms of dry AMD were treated and compared with a control group of 10 untreated patients with dry AMD. The target parameter was the visual acuity, as determined with the ETDRS logMAR charts. Other examinations performed during the study were tests of contrast vision, colour vision and central visual fields, as well as autofluorescence and fluorescein angiography and multifocal electroretinography. RESULTS: On termination of the infusions, six patients showed an increase in visual acuity by at least one line, an improvement that was seen in eight patients 2 months after the end of the infusion therapy. After 6 months, one patient exhibited an improvement of visual acuity by three lines and three patients an improvement by one line. Five patients were found to show no change of their baseline acuity values after 6 months, while two patients exhibited an impairment by one line. The visual acuity in the dry AMD control group without PGE1 treatment had decreased by 0.8 lines on the average after 6 months. Contrast vision, central visual fields and the multifocal electroretinogram showed improvements on the termination of infusions and up to 2 months later; no substantial change of these parameters, as compared with the baseline findings, was seen 6 months after the termination of infusions. SUMMARY: This pilot study suggests that PGE1 infusions have a stabilizing or improving effect on the visual acuity of patients with dry AMD. Owing to the limitations of a pilot study, these results should, however, be validated in a larger, randomized and blinded study.


Assuntos
Alprostadil/administração & dosagem , Alprostadil/uso terapêutico , Síndromes do Olho Seco/complicações , Síndromes do Olho Seco/tratamento farmacológico , Degeneração Macular/complicações , Degeneração Macular/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Infusões Intralesionais , Masculino , Projetos Piloto , Leitura , Testes Visuais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...